Tyra Bioscience (TYRA)
NASDAQ:TYRA
Want to see TYRA full AI Analyst Report?
TYRA Stock Chart & Stats
$35.56
-$0.12(-0.75%)
At close: 4:00 PM EST
$35.56
-$0.12(-0.75%)
Day’s Range― - ―
52-Week Range$8.75 - $40.65
Previous CloseN/A
Volume80.11K
Average Volume (3M)370.94K
Market Cap
$2.09B
Enterprise Value$1.75B
Total Cash (Recent Filing)$256.00M
Total Debt (Recent Filing)$5.81M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding59,485,237
10 Day Avg. Volume580,167
30 Day Avg. Volume370,944
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)6.05
Price to Sales (P/S)0.00
P/FCF Ratio-16.45
Enterprise Value/Market Cap0.84
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-6.44K
Enterprise Value/Ebitda-14.66
Forecast
1Y Price Target
$51.00Price Target Upside43.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.39
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Administration & Patient ConvenienceAn oral pill formulation avoids repeated invasive bladder procedures required by competitors, offering a more convenient treatment path for patients with non‑muscle‑invasive bladder cancer.
Pipeline Focus & Regulatory MilestonesA pivotal‑intent trial for low‑grade upper tract urothelial carcinoma and upcoming Phase II readouts serve as clear clinical catalysts that could materially increase program valuation if outcomes are favorable.
Target Selectivity & TolerabilitySelective FGFR3 inhibition is engineered to reduce off‑target side effects seen with pan‑FGFR drugs, potentially permitting higher tolerable doses and improved long‑term patient adherence.
Bears Say
Clinical Development UncertaintyEarly‑stage programs and incomplete efficacy readouts leave substantial uncertainty about regulatory approval and commercial success until larger trials confirm safety and durable responses.
Dose‑Related Off‑Target ToxicityHigh doses that maximize FGFR3 inhibition have produced off‑target toxicities related to other FGFR isoforms, creating safety concerns that could limit dosing strategies and market adoption.
Financial Dependence On Clinical SuccessContinued operating losses increase reliance on positive clinical readouts to justify further investment, heightening downside risk if trial results fail to meet expectations.
Tyra Bioscience News
TYRA FAQ
What was Tyra Bioscience’s price range in the past 12 months?
Tyra Bioscience lowest stock price was $8.75 and its highest was $40.65 in the past 12 months.
What is Tyra Bioscience’s market cap?
Tyra Bioscience’s market cap is $2.09B.
When is Tyra Bioscience’s upcoming earnings report date?
Tyra Bioscience’s upcoming earnings report date is Aug 06, 2026 which is in 92 days.
How were Tyra Bioscience’s earnings last quarter?
Currently, no data Available
Is Tyra Bioscience overvalued?
According to Wall Street analysts Tyra Bioscience’s price is currently Undervalued.
Does Tyra Bioscience pay dividends?
Tyra Bioscience does not currently pay dividends.
What is Tyra Bioscience’s EPS estimate?
Tyra Bioscience’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tyra Bioscience have?
Tyra Bioscience has 59,485,237 shares outstanding.
What happened to Tyra Bioscience’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tyra Bioscience?
Currently, no hedge funds are holding shares in TYRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tyra Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.00 (43.42% Upside)
$51.00 (43.42% Upside)
Hedge Fund Trend
Increased
By 951.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $528.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.61%
12-Months-Change
Fundamentals
Return on Equity
-41.17%
Trailing 12-Months
Asset Growth
-22.20%
Trailing 12-Months
Company Description
Tyra Bioscience
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
TYRA Stock 12 Month Forecast
Average Price Target
$51.00
▲(43.42% Upside)
Technical Analysis
KalVista Pharmaceuticals
―
Palvella Therapeutics
―
Gossamer Bio
―
Nurix Therapeutics
―
Terns Pharmaceuticals
―
Ownership Overview
29.54% Insiders
4.35% Mutual Funds
7.88% Other Institutional Investors
51.56% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---